Category: 141940-37-6

Mazzeo, Giuseppe; Longhi, Giovanna; Abbate, Sergio; Palomba, Martina; Bagnoli, Luana; Marini, Francesca; Santi, Claudio; Han, Jianlin; Soloshonok, Vadim A.; Di Crescenzo, Emilio; Ruzziconi, Renzo published an article in 2017, the title of the article was Solvent-free, uncatalyzed asymmetric “ene” reactions of N-tert-butylsulfinyl-3,3,3-trifluoroacetaldimines: a general approach to enantiomerically pure α-(trifluoromethyl)tryptamines.Recommanded Product: 141940-37-6 And the article contains the following content:

A novel approach to regioselectively substituted and stereoselectively α-trifluoromethylated tryptamines, e.g., I [Y = H, Me-5, OMe-5, Cl-5, F-5, CF3-5 or CF3-6] and II, is reported based on the ene reaction of Boc-protected 3-methyleneindolines with optically pure (R)- or (S)-tert-butanesulfinyltrifluoroacetaldimine. Boc- and sulfinylamido-protected α-trifluoromethyltryptamines are obtained in 60-70% yield and 85/15 dr by just heating equimolar amounts of the two reaction partners at 80-90 °C for 2-3 h without a solvent. The absolute configuration of the amino α-carbon has been assigned based on the vibrational CD (VCD) spectral anal. The two protecting group can be chemoselectively removed allowing further regio- and stereoselective elaboration of the ene products to various biol. interesting compounds The experimental process involved the reaction of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate(cas: 141940-37-6).Recommanded Product: 141940-37-6

The Article related to butylsulfinyl trifluoroacetaldimine stereoselective ene reaction boc protected methyleneindoline, trifluoromethyltryptamine preparation absolute configuration vibrational cd dft, regioselective elaboration trifluoromethyltryptamine, stereoselective elaboration trifluoromethyltryptamine and other aspects.Recommanded Product: 141940-37-6

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On March 10, 2005, Kumagai, Toshihito; Kuwada, Takeshi; Shibata, Tsuyoshi; Hayashi, Masato; Fujisawa, Yuri; Sekiguchi, Yoshinori published a patent.Computed Properties of 141940-37-6 The title of the patent was Preparation of 1-[1-(benzenesulfonyl)-3-phenyl-2-oxo-1,3-dihydro-2H-indol-3-yl]-4-fluoro-L-proline derivatives as antagonists of arginine-vasopressin V1b receptor. And the patent contained the following:

1,3-Dihydro-2H-indol-2-one derivatives represented by the formula (I) (wherein R1 = halogeno, C1-4 alkyl, C1-4 alkoxy, CF3, CF3O; R2 = H, halogeno, C1-4 alkyl, C1-4 alkoxy, CF3; or R2 is present in the 6-position of the indol-2-one and is bonded to R1 to form C3-6 alkylene; R3 = halogeno, hydroxy, C1-4 alkyl, C1-4 alkoxy, CF3O; R4 = H, halogeno, C1-4 alkyl, C1-4 alkoxy; or R4 is present in the 3-position of the Ph and is bonded to R3 to form methylenedioxy; R5 = H, F; R6 = ethylamino, dimethylamino, azetidin-1-yl, C1-4 alkoxy; R7, R8 = C1-4 alkoxy) or pharmaceutically acceptable salts thereof are prepared These compounds have antagonistic activity against an arginine-vasopressin V1b receptor and are useful for the prevention or treatment of depression, anxiety, Alzheimer’s disease, Parkinson’s disease, Huntington chorea, eating disorder, hypertension, digestive tract diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head trauma, inflammation, immune diseases, and alopecia. Thus, 3.78 g 3,5-dichloro-3-(2-methoxyphenyl)-1,3-dihydro-2H-indol-2-one and 7.27 g (4R)-4-fluoro-N,N-dimethyl-L-prolinamide trifluoroacetate were suspended in 40 mL CHCl3, treated with 7.47 g Et3N, and stirred at room temperature for 13 h to give, after silica gel chromatog., (+)- and (-)-(4R)-1-[5-chloro-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-fluoro-N,N-dimethyl-L-prolinamide (II). (-)-II (2.00 g) was added to a mixture of 0.215 g NaH and 20 mL DMF under ice-cooling, stirred for 40 min, treated with a solution of 1.27 g 2,4-dimethoxybenzenesulfonyl chloride in 5 mL DMF, and stirred for 35 min under ice-cooling and then at room temperature for 1 h to give (-)-(4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-fluoro-N,N-dimethyl-L-prolinamide (III). III inhibited the binding of [3H]Arg-vasopressin to arginine-vasopressin receptor VIb and VIa by 50% at 1-100 x 10-9 M and 10-8-10-6 M, resp. The experimental process involved the reaction of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate(cas: 141940-37-6).Computed Properties of 141940-37-6

The Article related to benzenesulfonylphenyloxodihydroindolylfluoroproline preparation antagonist arginine vasopressin v1b receptor, oxodihydroindolylfluoroprolinamide preparation antagonist arginine vasopressin v1b receptor, oxodihydroindolylfluoroproline preparation antagonist arginine vasopressin v1b receptor and other aspects.Computed Properties of 141940-37-6

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On December 4, 2008, Sugita, Kazuyuki; Otsuka, Masaki; Oki, Hitoshi; Haginoya, Noriyasu; Ichikawa, Masanori; Ito, Masao published a patent.Safety of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate The title of the patent was Preparation of tricyclic compounds such as pyrrolobenzoxazepine derivatives and analogs thereof for treatment of hypercholesteremia, hyperlipemia, and arteriosclerosis. And the patent contained the following:

The title compounds [I; R1 = aryl or heteroaryl which may have 1 to 3 substituents; R2, R2a = H, halo, cyano, etc.; R3 = H, halo, alkyl, etc.; R4 = carboxyl, carboxycarbonyl, carboxyalkenyl, etc.; X = CH2, O, S; Y = N, CR3a; R3a = same as defined for R3; Z = N, CR3aa; R3aa = same as defined for R3; ring (N) = benzene or pyridine ring] are prepared I inhibit squalene synthetase and cholesterol synthesis. Thus, 2-(2-(2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-10-fluoro-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]ethyl)-2H-1,2,3,4-tetrazol-5-yl)acetic acid was prepared in a multistep process starting from 2-bromo-4-chloro-6-fluoroaniline and 2,5-dimethoxytetrahydrofuran. Compounds of this invention showed IC50 values of 0.56 nM to 7.6 nM against rat squalene synthetase. The experimental process involved the reaction of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate(cas: 141940-37-6).Safety of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate

The Article related to pyrrolobenzoxazepine derivative analog preparation hypercholesteremia hyperlipemia arteriosclerosis treatment, squalene synthetase cholesterol synthesis inhibitor pyrrolobenzoxazepine derivative analog preparation, tricyclic compound preparation hypercholesteremia hyperlipemia arteriosclerosis treatment and other aspects.Safety of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On May 18, 2007, Sugita, Kazuyuki; Otsuka, Masami; Oki, Hitoshi; Haginoya, Noriyasu; Ichikawa, Masanori; Itoh, Masao published a patent.Recommanded Product: tert-Butyl (4-(trifluoromethyl)phenyl)carbamate The title of the patent was Preparation of tricyclic compounds such as pyrrolobenzoxazepine derivatives and analogs thereof for treatment of hypercholesteremia, hyperlipemia, and arteriosclerosis. And the patent contained the following:

The title compounds I [R1 = aryl or heteroaryl which may have 1 to 3 substituents; R2, R2a = H, halo, cyano, etc.; R3 = H, halo, alkyl, etc.; R4 = carboxyl, carboxycarbonyl, carboxyalkenyl, etc.; X = CH2, O, S; Y = N, CR3a; R3a = same as defined for R3; Z = N, CR3aa; R3aa = same as defined for R3; ring (N) = benzene or pyridine ring] are prepared I inhibit squalene synthetase and cholesterol synthesis. Thus, 2-(2-(2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-10-fluoro-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]ethyl)-2H-1,2,3,4-tetrazol-5-yl)acetic acid was prepared in a multistep process starting from 2-bromo-4-chloro-6-fluoroaniline and 2,5-dimethoxytetrahydrofuran. Compounds of this invention showed IC50 values of 0.56 nM to 7.6 nM against rat squalene synthetase. The experimental process involved the reaction of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate(cas: 141940-37-6).Recommanded Product: tert-Butyl (4-(trifluoromethyl)phenyl)carbamate

The Article related to pyrrolobenzoxazepine derivative analog preparation hypercholesteremia hyperlipemia arteriosclerosis treatment, squalene synthetase cholesterol synthesis inhibitor pyrrolobenzoxazepine derivative analog preparation, tricyclic compound preparation hypercholesteremia hyperlipemia arteriosclerosis treatment and other aspects.Recommanded Product: tert-Butyl (4-(trifluoromethyl)phenyl)carbamate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On August 3, 2006, Sekiguchi, Yoshinori; Kuwada, Takeshi; Hayashi, Masato; Nozawa, Dai; Amada, Yuri; Shibata, Tsuyoshi; Yamamoto, Shuji; Ohta, Hiroshi; Okubo, Taketoshi; Koami, Takeshi published a patent.Related Products of 141940-37-6 The title of the patent was Preparation of 1,3-dihydro-2H-indol-2-one compounds and pyrrolidin-2-one compound fused with aromatic heterocycle as antagonists of arginine-vasopressin V1b receptor. And the patent contained the following:

The title compounds [I; ring A = each (un)substituted C6-14 aryl or aromatic heterocyclyl; P = a single bond, C1-5 alkylene; Q = each (un)substituted C6-14 aryl or aromatic heterocyclyl, Q1; RD and RE at 2 and 3 or 3 and 4 positions together form (un)substituted C1-3 alkylenedioxy, (CH2)m-O, N-(un)substituted (CH2)m-NH or NH-(CH2)m, (CH2)m-S, O-(CH2)m-S, or S-(CH2)m-S (m = 2-4); R5 = Q2, Q3, etc.; R6 = H, halo, (un)substituted HO; R7 = H, halo, (un)substituted SH; or R6 and R7 together represent oxo; R9 = each (un)substituted OH, SH or NH2; R33 = H, (un)substituted C1-5 alkyl, C3-8 cycloalkyl, C1-5 alkoxycarbonyl, C6-14 aryl, heterocyclyl; RA, RB, RC = H, halo, NO2, NH2, hydroxyamino, C1-5 alkyl, C1-5 alkoxy, C1-5 alkylthio, etc.] or pharmacol. acceptable salts thereof are prepared These compounds are highly selectively antagonistic to arginine-vasopressin V1b receptor over arginine-vasopressin V1a receptor and arginine-vasopressin V2 receptor, have high metabolic stabilities and show favorable migration into the brain and high concentrations in the plasma. They provide drugs which are efficacious against pathol. conditions relating to arginine-vasopressin V1b receptor. More particularly speaking, they provide drugs which have a therapeutic or preventive effect on depression, anxiety, Alzheimer’s disease, Parkinson’s disease, Huntington’s chorea, eating disorders, hypertension, digestive diseases, drug addiction, epilepsy, brain infarction, brain ischemia, brain edema, head injury, inflammation, immune diseases, alopecia and so on. Thus, reductive amination of (4R)-1-((3R)-5-Chloro-3-[2-methoxy-5-(2-oxoethyl)phenyl]-1-([4-methoxy-2-(trifluoromethoxy)phenyl]sulfonyl)-2-oxo-2,3-dihydro-1H-indol-3-yl)-4-hydroxy-N,N-dimethyl-L-prolinamide with piperidine using sodium triacetoxyborohydride in the presence of acetic acid din a mixture of THF and CHCl3 gave (+)-(4R)-1-[5-Chloro-3-[5-[2-(dimethylamino)ethyl]-2-methoxyphenyl]-1-[[4-methoxy-2-(trifluoromethoxy)phenyl]sulfonyl]-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-L-prolinamide (II). II inhibited the binding of [3H](Arg8)vasopressin to human arginine vasopressin V1b, V1a, and V2 receptor with IC50 of 0.32, 102, and 5,050, nM, resp. The experimental process involved the reaction of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate(cas: 141940-37-6).Related Products of 141940-37-6

The Article related to phenylsulfonylindolylprolinamide preparation antagonist arginine vasopressin v1b receptor, dihydroindolone preparation antagonist arginine vasopressin v1b receptor, pyrrolidinone fused heterocycle preparation antagonist arginine vasopressin v1b receptor, depression anxiety alzheimer disease treatment dihydroindolone preparation and other aspects.Related Products of 141940-37-6

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Zhang, Xue; Ling, Liang; Luo, Meiming; Zeng, Xiaoming published an article in 2019, the title of the article was Accessing Difluoromethylated and Trifluoromethylated cis-Cycloalkanes and Saturated Heterocycles: Preferential Hydrogen Addition to the Substitution Sites for Dearomatization.Related Products of 141940-37-6 And the article contains the following content:

A straightforward process in which a cyclic (alkyl)(amino)carbene/Rh catalyst system facilitates preferential addition of hydrogen to substitution sites of difluoromethylated and trifluoromethylated arenes and heteroarenes, leading to dearomative reduction was reported. This strategy enabled diastereoselective synthesis of cis-difluoromethylated and cis-trifluoromethylated cycloalkanes such as I [R = 2-COMe, 4-pyrazolyl, 3-OTBS, etc.; R1 = CF2H, CF3] and saturated heterocycles, e.g. II, and even allowed formation of all-cis multi-trifluoromethylated cyclic products with a defined equatorial orientation of the di- and trifluoromethyl groups. Deuterium-labeling studies indicated that hydrogen preferentially attacked substitution sites of planar arenes, resulting in dearomatization, possibly with heterogeneous Rh as reactive species, followed by either reversible or irreversible hydrogen addition to nonsubstitution sites. The experimental process involved the reaction of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate(cas: 141940-37-6).Related Products of 141940-37-6

The Article related to difluoromethyl cis cycloalkane saturated heterocycle diastereoselective preparation, arene heteroarene cycloalkyl amino carbene rhodium catalyst dearomative reduction, trifluoromethyl cis cycloalkane saturated heterocycle diastereoselective preparation, heteroarene arene cycloalkyl amino carbene rhodium catalyst dearomative reduction and other aspects.Related Products of 141940-37-6

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On January 25, 2007, Uchida, Hideharu; Kosuga, Naoto; Satoh, Tsutomu; Hotta, Daido; Kamino, Tomoyuki; Maeda, Yoshitaka; Amano, Ken-Ichi; Akada, Yasushige published a patent.Quality Control of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate The title of the patent was Preparation of novel 2-(bicyclic heterocyclidene)acetamide derivatives as antagonists of transient receptor potential type 1 (TRPV1). And the patent contained the following:

The title compounds (I) or salts thereof, and solvates of any of them [m, n, p = an integer of 0-2; q = 0, 1; R1 = halo, each (un)substituted hydrocarbyl, heterocyclyl, C1-6 alkoxy, C1-6 alkoxycarbonyl, NH2, HO, CO2H, CONH2, or SO2NH2, C1-6 alkanoyl, C1-6 alkylthio, C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, cyano, NO2; R2 = halo, (un)substituted NH2, hydrocarbyl, or aromatic heterocyclyl, oxo; or two geminal or vicinal R2s together form C2-6 alkylene; R2 and the carbon atom attached to R2 together form a cyclic ring; X1 = O, (un)substituted NH, S, SO, SO2; X2 = CH2, O, (un)substituted NH, S, SO, SO2; Q1 = each (un)substituted heteroaryl, heteroarylalkyl, aryl, or aralkyl; the Cy ring = 5- or 6-membered aryl or heteroaryl; a dotted line represents the condensation of two rings; a wavy line represent E or Z configuration; some exceptions are defined] are prepared These compounds are useful for the treatment or prevention of pains. Thus, tri-Et phosphonoacetate was treated with NaH in THF at ≤20° for 1 h and condensed with 4-chromanone at room temperature overnight to give (E)-(chroman-4-ylidene)acetic acid Et ester which was refluxed in aqueous THF solution containing LiOH and neutralized with 1 N aqueous HCl solution to give (E)-(chroman-4-ylidene)acetic acid (II). II was condensed with 1,4-benzodioxan-6-amine using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride in CH2Cl2 at room temperature overnight to give (E)-2-(chroman-4-ylidene)-N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)acetamide (III). III and (E)-2-(8-trifluoromethyl-3,4-dihydrobenzo[b]oxepin-5(2H)-ylidene)-N-(quinoxalin-6-yl)acetamide in vitro showed A2 of ≥100 nM and <100 nM, resp., for antagonizing the capsaicin-induced cellular influx of Ca in CHO cell expressing human TRPV1. Pharmaceutical formulations, e.g. a tablet containing (E)-2-(7-tert-Butylchroman-4-ylidene)-N-(5,6,7,8-tetrahydroquinolin-7-yl)acetamide, were prepared The experimental process involved the reaction of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate(cas: 141940-37-6).Quality Control of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate

The Article related to capsaicin receptor trpv1 antagonist bicyclic heterocyclideneacetamide preparation, bicyclic heterocyclideneacetamide preparation antagonist transient receptor potential type 1, chromanylideneacetamide benzooxepinylideneacetamide preparation treatment prevention pain, pain treatment prevention bicyclic heterocyclideneacetamide preparation and other aspects.Quality Control of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On June 10, 2004, Fujimoto, Roger Aki; McQuire, Leslie Wighton; Monovich, Lauren G.; Mugrage, Benjamin Biro; Parker, David Thomas; Van Duzer, John Henry; Wattanasin, Sompong published a patent.Formula: C12H14F3NO2 The title of the patent was Preparation of substituted amino phenylacetic acids and derivatives and their use as cyclooxygenase-2 (COX-2) inhibitors. And the patent contained the following:

The title compounds I (R = H, alkyl, cycloalkyl, halo, alkoxy, F3CO, Me3C, cyano, R1 = biaryl, β-naphthyl derivative, bicyclic heterocyclic aryl, cycloalkyl monocyclic carbocyclic aryl, cycloalkane fused-monocyclic carbocyclic aryl) were prepared Thus, N,N-dimethyl-2-(2′,3′,5′,6′-tetrafluoro-4′-phenylanilino)phenylacetamide was hydrolyzed to give I (R = H, R1 = 4-PhC6F4). The experimental process involved the reaction of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate(cas: 141940-37-6).Formula: C12H14F3NO2

The Article related to phenylacetic acid amino preparation cyclooxygenase 2 inhibitor, rheumatoid arthritis inhibitor aminophenylacetic acid, osteoarthritis inhibitor aminophenylacetic acid, dysmenorrhea inhibitor aminoophenylacetic acid, pain inhibitor aminophenylacetic acid, neoplasm inhibitor aminophenylacetic acid, inflammation inhibitor aminophenylacetic acid and other aspects.Formula: C12H14F3NO2

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On April 25, 2020, Escobar, Randolph A.; Johannes, Jeffrey W. published an article.Application In Synthesis of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate The title of the article was A Unified and Practical Method for Carbon-Heteroatom Cross-Coupling using Nickel/Photo Dual Catalysis. And the article contained the following:

A general method that allows for C-O, C-N and C-S cross-coupling reactions under one general set of conditions has been described. An energy transfer pathway, in which an iridium photosensitizer produces an excited nickel(II) complex, is responsible for the key reductive elimination step that couples aryl halides RX (R = C6H5, 4-CF3C6H4, 3-pyridyl, etc.; X = Cl, Br, I) to 1° R1CH2OH (R1 = C6H5, 2-thienyl, 3-pyridyl, etc.) and 2° alcs. R2R3CHOH (R2 = Me, (CH2)2CH3, C6H5; R3 = Me; R2R3 = -(CH2)5-, R2R3 = -(CH2)4-, R2R3 = -(CH2)3-), amines R4NH2 (R4 = (CH2)3CH3, C6H5, 2-naphthyl, etc.) and 1-phenylethan-1-amine, thiols R5SH (R5 = C6H5, 2-naphthyl, cyclopentyl, etc.), carbamates R6OC(O)NH2 (R6 = t-Bu, Bn, allyl), and benzenesulfonamide, and is amenable to scale up via a flow app has been discussed. The experimental process involved the reaction of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate(cas: 141940-37-6).Application In Synthesis of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate

The Article related to ether preparation, alc aryl halide cross coupling nickel iridium dual photocatalyst, amine aryl halide cross coupling nickel iridium dual photocatalyst, thiol aryl halide cross coupling nickel iridium dual photocatalyst, carbamate aryl halide cross coupling nickel iridium dual photocatalyst, cross-coupling, dual catalysis, nickel catalysis, photocatalysis and other aspects.Application In Synthesis of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On February 29, 2008, Bellezza, Francesca; Cipiciani, Antonio; Ruzziconi, Renzo; Spizzichino, Sara published an article.Recommanded Product: 141940-37-6 The title of the article was Nucleus- and side-chain fluorinated 3-substituted indoles by a suitable combination of organometallic and radical chemistry. And the article contained the following:

Regioselectively fluoro-, trifluoromethyl- and trifluoromethoxy-substituted 3-methyleneindolines e.g., I, have been prepared using a four-step procedure involving metalation/bromination of fluorinated Boc-protected anilines, N-propargylation of the resulting o-bromoarylcarbamate and reductive radical cyclization of the product with tributyltin hydride/AIBN. 3-Methyleneindolines, as valuable, versatile intermediates, can be transformed into highly functionalized 3-substituted indoles by ene-type reactions using different enophiles. Thus, fluoro-, trifluoromethyl- and trifluoromethoxy-substituted di-Et 2-hydroxy-2-[(1H-indol-3-yl)methyl]malonates, e.g., II, Et 2-hydroxy-3-(1H-indol-3-yl)propionates, e.g. III, and Et 2-hydroxy-3-(1H-indol-3-yl)-2-trifluormethylpropionates, e.g., IV, were obtained in 77-86% yield by simply heating the corresponding tert-Bu 3-methyleneindoline-1-carboxylate with an equimolar amount of di-Et ketomalonate, Et glyoxalate and Et 3,3,3-trifluoropyruvate, resp., at 100 °C, without solvent, for 0.5-4 h. The experimental process involved the reaction of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate(cas: 141940-37-6).Recommanded Product: 141940-37-6

The Article related to aniline butyllithium carbon tetrabromide lithiation bromination, ortho bromo aniline preparation base propargyl bromide alkylation, propargyl aniline preparation aibn tributyltin hydride radical cyclization, indoline preparation enophile carbonyl ene reaction, indole hydroxy propionate derivative preparation, hydroxy malonate indole derivative preparation and other aspects.Recommanded Product: 141940-37-6

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics